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Abstract The spinocerebellar ataxia type 23 locus was
identified in 2004 based on linkage analysis in a large, two-
generation Dutch family. The age of onset ranged 43–
56 years and the phenotype was characterized by a slowly
progressive, isolated ataxia. Neuropathological examination
revealed neuronal loss in the Purkinje cell layer, dentate
nuclei, and inferior olives. Ubiquitin-positive intranuclear
inclusions were found in nigral neurons, but were consid-
ered to be Marinesco bodies. The disease locus on
chromosome 20p13-12.3 was found to span a region of
approximately 6 Mb of genomic DNA, containing 97
known or predicted genes. To date, no other families have
been described that also map to this SCA locus. Direct
sequencing of the coding regions of 21 prioritized candidate
genesdidnotrevealanydisease-causingmutation.Apparently,
theSCA23geneisadiseasegenewithadifferentfunctionthan
the genes that have been associated with other known SCA
types. Work to elucidate the chromosomal organization of the
SCA23 locus will eventually discover the responsible disease
gene.
Introduction
Autosomal dominant cerebellar ataxias (ADCA) comprises
a clinically and genetically heterogeneous group of neuro-
degenerative disorders characterized by a cerebellar ataxic
syndrome. As most of the disease phenotypes no longer fit
into the categories defined by Harding [1], ADCA is now
classified by the causal mutation or gene locus. So far 26
different subtypes of ADCA have been recognized and are
known as the spinocerebellar ataxias (SCA1-8, 10–29) [2, 3].
The SCA9 locus has been reserved since 2001 but there is
still no publication about it, while SCA19 and SCA22 may
be allelic diseases. However, the disease gene and causal
mutation has been identified in just 17 SCA types (SCA1-7,
10–17, 27 and 28) [2, 4–7].
The most recent SCA mutations identified are not like
the first mutations, which coded CAG (glutamine) or non-
coding repeat expansions (SCA1-3, 6–8, 10, 12, and 17)
[2]; rather they are missense, deletion or duplication
mutations (SCA14, 4–5, 11, 13–16, 20 and 28) [2, 5–8].
The different disease-causing mechanisms have changed
the view on the pathology of the disorder, as it is no longer
considered to be a “pure” polyglutamine disorder, such as
Huntington’s disease or Kennedy’s disease. The fact that
different mutational mechanisms in various disease genes
lead to similar disease phenotypes strongly suggests that
common biological pathways must underlie the different
SCA types.
Worldwide, SCA3 mutations display a prevalence of 20–
25%, but there are regional variations [9, 10]. SCA1, 2, 6,
and 7, on average displayed a prevalence of approximately
2–5% [11]. However, the SCA1 mutation is most frequently
identified in Africa [12], while SCA2 accounts for most of
the cases in India, Cuba, and Italy [13, 14]. The remaining
SCA types are considered to be rare mutations, identified in
singular families or specific populations, and do not explain
the majority of the unclassified SCA cases. Thus, the
heterogeneity of the disorder is reflected by how the
prevalence varies between different ethnic and continental
groups and moreover indicates that novel SCA genes still
need to be found.
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ADCA family with a slowly progressive, isolated ataxia
[15], with no mutations in the SCA genes known then
(SCA1-3, 6–8, 12 and 17). Genome-wide linkage analysis
in 14 family members mapped the new disease gene to
chromosome region 20p13-12.3. As this region was not
known to be involved in ADCA, their disorder was
designated as spinocerebellar ataxia type 23 (SCA23) by
the Human Genome Nomenclature Committee.
Clinical Observations
The pattern of disease transmission in the SCA23 family
was consistent with an autosomal dominant inheritance.
There were no affected individuals of the first generation
still alive at the time of the assessment, so no clinical data
could be obtained. The presence of clinical anticipation
could not therefore be confirmed. In the 2004 study, we
examined five second-generation individuals with a mean
age of onset of 50.4 years (range 43–56 years) and a mean
duration of clinical symptoms at examination of 10.2 years
(range 1–23 years). Based on these data, the disease
progression seemed to be relatively slow and the disease
severity correlated with the duration of the disease, as
wheelchair dependence only occurred 23 years after onset
of the disease.
The initial symptom in three patients was gait ataxia and
in two of the patients it was cycling difficulties and a
concurrent decline of gait and speech. In these latter
patients, gait ataxia followed somewhat later after the first
symptoms presented. All patients showed a relatively
slowly progressive, isolated, cerebellar ataxia without any
distinctive features such as cognitive deterioration, epilepsy,
extrapyramidal features, or peripheral nerve involvement.
Additional neurological examination revealed dysarthria,
oculomotor problems such as slowing saccades and ocular
dysmetria, and decreased vibration sense below the knee in
three affected individuals. Four patients showed hyper-
reflexia and two displayed Babinski’s signs.
Not much is known on the clinical variability as only
one family has been described. SCA23 may only have a
few symptoms besides the gait ataxia and is referred to as a
“pure” ataxia, similar to SCA5-6, 11, 15–16, and 22 [11].
Neuropathology
Macroscopic examination of the brain of one SCA23
patient showed marked atrophy of the frontotemporal
region and vermis of the cerebellum, the basis pontis, and
the spinal cord. The weight of the brain (930 g) reflected
the large loss of tissue due to the disease. Pronounced
neuronal loss was identified in the Purkinje cell layer of the
rostal vermis, the dentate nuclei and inferior olives; the
surrounding white matter showed myelin loss and gliosis.
Although normal myelination was seen of the white matter
tracts in the basis pontis, the cerebellopontine tracts were
relatively small. No clear loss of motor neurons was
observed in the spinal cord.
Neuropathological studies of the SCA types that have
recently been genetically defined are rare and are often
performed on the autopsies of patients who had end-stage
disease. However, some reports describe detailed morpho-
logical findings on SCA1-3, 6, and 7 [11]. If we compare
the pathological features of the SCA23 brain with other
SCA types, it mostly closely resembles SCA6 pathology, as
only marked atrophy was observed in the cerebellum with
specific loss of the Purkinje cells and neuronal loss in the
inferior olives. No massive cell loss was detected in the
substantia nigra or pons, which is often seen in SCA1-3
pathology and is probably associated with the severity and
progression of these subtypes.
Ubiquitin-positive neural inclusions (2–5 μmi nd i a m e t e r )
were detected in some of the nigral neurons. However, these
inclusions did not resemble those protein aggregates fre-
quently correlated with polyglutamine-induced SCA types
and were considered to be Marinesco bodies. Neurons in the
substantia nigra occasionally contained Lewy bodies. Addi-
tional neurodegenerative deposits observed using different
immuno-histochemical stainings (e.g. Bodian silver and β-
amyloid) were generally rare or absent. However, some
micro- and astroglia cells in and around the central nuclei
and substantia nigra were positive for tau-staining.
Gene Mapping and Molecular Studies
As regular diagnostic screening and linkage analysis
excluded the known SCA genes and loci, we performed a
genome-wide screen in an attempt to map the disease gene.
Two-point linkage analysis revealed significant linkage
with marker D20S199 (max. lod score 3.46). The candidate
interval was located directly on the tip of the short arm of
chromosome 20 and was flanked proximally by marker
D20S1155. The region spans 18.2 cM in size, which
corresponds to approximately 6 Mb of genomic DNA,
and contains 97 predicted and known transcripts.
Genes containing a coding CTG or CAG repeat were
considered to be primary candidate genes for SCA23
disease. This resulted in the identification of three genes
in the SCA23 interval: GFR receptor α-4 (GFRA4),
attractin (ATRN), and ubiquitin-conjugating enzyme 7
interacting protein 3 (RBCK1). However, no polyleucine
or polyglutamine repeat expansions were observed in these
genes using Southern blotting. Three additional genes were
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ataxic phenotype in gene-specific mutant mice, including
neuronal death inducible kinase (SKIP3), major prion
protein precursor (PRNP), and the prion gene complex
downstream (PRND). Direct sequencing of the coding
regions and intron–exon boundaries of the selected genes
did not reveal any disease-causing alterations.
After this exclusion, an alternative approach was taken.
The notion that different mutational mechanisms in diverse
genes lead to identical disease phenotypes strongly suggests
that common biological pathways must underlie the
different SCA types. Therefore, a protein–protein interaction
network was developed for 20 different inherited cerebellar
ataxias [16]. This network analysis revealed several unsus-
pected interactions between the diverse disease proteins and
it also harbors potentially new disease candidate genes for
the SCA loci in which no disease gene has been identified
yet.
In order to prioritize the 97 SCA23 candidate disease
genes, the protein interaction data available from the ataxia
network and the Prioritizer program was used [17]. This
program prioritizes candidate genes in the SCA23 interval,
based on the position that these genes are given in a gene
network founded on the knowledge of the known SCA
genes. This resulted in the identification of three genes in
the SCA23 interval that were shown to be physical
interaction partners of known ataxia genes in the yeast
two-hybrid screen: proteasome inhibitor PI31 subunit
(PSMF1), FK506 binding protein 1A (FKBP1A), and
isocitrate dehydrogenase 3 (NAD+) beta (IDH3B)[ 16].
These three potential candidates were screened for muta-
tions in the coding regions and intron–exon boundaries via
direct sequencing but no mutations were found. Using the
Prioritizer program, an additional 18 candidate genes from
the SCA23 region were selected based on their p value (the
lower the p value the more likely that this gene is indeed
the SCA23 disease gene) and gene function (Table 1).
Unfortunately, extensive sequencing of annotated exons
and exon–intron boundaries did not identify any disease-
causing mutation. Twenty-four single nucleotide polymor-
phisms (SNPs) were detected in 17 exons of the 18 genes
(data not shown). From these SNPs, only one of the
variations was unknown in the Ensembl SNP database
(release 50, July 2008; www.ensembl.org/snpview) and was
located in exon 1 (c.136A>G) of the ADRA1 gene and
changed the amino acid serine to glycine. However, this
change seemed to be tolerated as it was also observed in
healthy controls, and additionally did not fully co-segregate
with the disease phenotype within the family. This variation
was not therefore considered to be a disease-causing
variation.
Discussion
SCA23 has so far been identified in one Dutch ADCA
family and is characterized by a slowly progressive isolated
cerebellar ataxia. As no other families have been found that
Table 1 Overview of sequenced prioritized candidate genes within SCA23 interval
Position prioitizer Gene p value Chr Start End
1 SNPH 0.0003998400639 20 1194960 1237969
2 GPR73L1 0.009196321471411436 20 5230686 5243015
3 NSFL1C 0.009596161535385846 20 1370811 1396417
4 GFRA4 0.012395041983206718 20 3587939 3592046
5 RASSF2 0.013594562175129948 20 4708670 4752291
6 FKBP1A 0.014394242303078768 20 1297623 1321745
7 ADRA1D 0.015193922431027589 20 4149816 4177659
8 TGM3 0.015593762495002 20 2224675 2269725
9 AVP 0.01599360255897641 20 3011203 3013370
11 SLC23A2 0.01639344262295082 20 4781002 4930145
12 PTPNS1 0.01719312275089964 20 1823425 1868532
14 CENPB 0.021591363454618154 20 3713331 3715130
17 PSMF1 0.025189924030387844 20 1041939 1095971
18 PTPRA 0.025989604158336666 20 2769373 2967314
19 UBOX5 0.025989604158336666 20 3036220 3088540
22 CSNK2A1 0.029188324670131948 20 411340 472482
23 ITPA 0.03078768492602959 20 3138056 3152504
27 CDC25B 0.032387045181927226 20 3724386 3734759
30 STK35 0.036785285885645745 20 2031519 2077196
36 SNRPB 0.04558176729308277 20 2390281 2399499
42 IDH3B 0.06717313074770093 20 2587043 2592853
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following-up the individuals in the second and third
generations presumed at-risk. We hope eventually to
narrow down the size of the SCA23 region and limit the
number of potential candidate genes. Reviewing the latest
data, the question arises: where is the disease gene and its
mutation? Despite the extensive molecular analysis of 24
genes that was based on good knowledge of the function
and expression of the candidate genes, we have been unable
to identify any disease-causing mutation. The newest
genetic data even suggest that SCA23 is caused by
mutations in a completely different gene than has been
described for the known SCA types so far, because we did
not even find mutations in the prioritized candidate genes.
As two of the more recent SCA types (15 and 20) were
caused by in-frame deletion and duplication mutations, it
will be necessary to use additional molecular approaches,
such as MLPA or array-based high-density SNP typing to
elucidate the chromosomal organization at the SCA23
locus.
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